EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A pharmacovigilance analysis of carbapenem-related utilizing the FDA adverse event reporting system (FAERS) database from 2013 to 2025

Connor Frey iD, Parham Elmi iD

Journal of Antimicrobial Chemotherapy · 2026

DOI: 10.1093/jac/dkag060 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Connor Frey und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of British Columbia, 2194 Health Sciences Mall, Vancouver, British Columbia V6T 1Z3, Canada. Hauptthemen laut MEDLINE: Carbapenems, Pharmacovigilance, Anti-Bacterial Agents, Adverse Drug Reaction Reporting Systems. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Carbapenem antibiotics are critical therapies for multidrug-resistant infections, but their comparative haematologic safety profiles remain poorly characterized. We systematically evaluated haematologic adverse events associated with meropenem, ertapenem, imipenem and doripenem using pharmacovigilance data.

Methods

We analyzed the FDA Adverse Event Reporting System (FAERS) database from January 2013 to July 2025. Disproportionality analysis was performed using reporting odds ratios (RORs) with 95% confidence intervals for haematologic adverse events.

Results

Sixteen distinct haematologic adverse events were identified. Meropenem demonstrated the most extensive toxicity profile with significant signals for 15 adverse events, including severe conditions: thrombocytosis (ROR = 24.941), eosinophilia (ROR = 24.663), bone marrow failure (ROR = 13.113), agranulocytosis (ROR = 11.57) and pancytopenia (ROR = 11.131). Imipenem demonstrated signals for nine events, notably thrombocytopenia and eosinophilia. Ertapenem demonstrated nine events: leucopenia (ROR = 3.843) and neutropenia (ROR = 2.469). No reports were identified for doripenem.

Conclusions

Significant differences exist in haematologic safety profiles among carbapenems. Meropenem shows the broadest spectrum of severe toxicity, while other carbapenems demonstrate fewer reports. demonstrates fewer reported haematologic safety signals and not a most favourable haematologic safety profile. These differential safety profiles should inform further studies on carbapenem selection, including patients with baseline haematologic disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CarbapenemsPharmacovigilanceAnti-Bacterial AgentsAdverse Drug Reaction Reporting SystemsDrug-Related Side Effects and Adverse ReactionsHumansUnited StatesUnited States Food and Drug AdministrationDatabases, FactualImipenemFemaleMeropenemMaleErtapenemMiddle AgedAdultDoripenemAged

Substanzen

CarbapenemsAnti-Bacterial AgentsImipenemMeropenemErtapenemDoripenem

Autor:innen und Institutionen

  • Department of Medicine, University of British Columbia, 2194 Health Sciences Mall, Vancouver, British Columbia V6T 1Z3, Canada.

ORCID-Profile: Connor Frey, Parham Elmi

Zitieren

APA

Frey, C., & Elmi, P. (2026). A pharmacovigilance analysis of carbapenem-related utilizing the FDA adverse event reporting system (FAERS) database from 2013 to 2025. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkag060

Vancouver

Frey C, Elmi P. A pharmacovigilance analysis of carbapenem-related utilizing the FDA adverse event reporting system (FAERS) database from 2013 to 2025. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkag060

BibTeX
@article{Frey2026,
  author = {Frey, Connor and Elmi, Parham},
  title = {A pharmacovigilance analysis of carbapenem-related utilizing the FDA adverse event reporting system (FAERS) database from 2013 to 2025},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  doi = {10.1093/jac/dkag060}
}
Kostenlos starten →